Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


Adverse Reactions Increase in Children with Use of Common Reflux Aids: Study


 

Proton Pump Inhibitors (PPIs) -- such as Prilosec, Protonix and Nexium, have long been one of the most prescribed medications in the country to aid in the reduction of stomach acid.

The use of these medicines among children is on the rise and so are potential side effects, which is sparking concern according to a recent study published in Pediatrics.

"CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections," a retrospective, biorepository, cohort study led by Sara Van Driest, MD, PhD, assistant professor of Pediatrics at Monroe Carell Jr. Children's Hospital at Vanderbilt, examined DNA from patients ages 0 to 3 years old at the time of PPI exposure.

"PPIs are commonly used in children to treat gastrointestinal disorders, and we are seeing an increase in the number of adverse infection events associated with their use," said Van Driest, the principal investigator of the study.

"Because these medications are available over the counter for adults, they are thought to be a safe option for children. These medicines are seen as very low risk with few downsides. But what we have found is that PPIs aren't without risk," she stressed.

According to Van Driest, there is a specific enzyme in the body, CYP2C19, that helps break down these medications. The enzyme works differently in each person - from slow, normal, fast and sometimes not at all -- impacting the ability of the medication to be safely metabolized.

Because CYP2C19 inactivates PPIs, genetic variants that decrease the enzyme's function may increase the medicine levels in the body leading to more infection events. Stomach acid naturally protects the body from dangerous organisms that can be found in water and food. Reducing stomach acid may increase an infant's risk of these kinds of infections.

The study included PPI-exposed infants, both healthy and those with chronic health conditions, with varying levels of enzyme function. In all, 670 individuals were included using BioVU samples, Vanderbilt's biorepository of DNA extracted from discarded blood collected during routine clinical testing.

The team hopes its findings will help clinicians make the best decisions on prescribing PPIs in children.

"The fact that children who have been characterized as normal CYP2C19 metabolizers actually had more infection events than the fast metabolizers tells us that being exposed to these drug levels actually puts the child at risk for having an extra infection event," said Van Driest.

"We were able to highlight that these medicines do have side effects, and as clinicians we need to think very carefully about the benefits and the risks. We can consider doing a genetic test to identify if a patient is a slow, normal or fast metabolizer."

Genetic testing can be a useful tool to determine if a patient requires a lower or higher dose of the drug.

At Vanderbilt, the PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment) genetic test is available to predict patient responses to drugs. Some people metabolize drugs abnormally, to the point of deriving no benefit from a particular drug or responding dangerously to a normal dose. These different drug responses increasingly are associated with different common genetic variants.

The study findings add to the growing evidence that CYP2C19's impact on PPIs warrants extra consideration when prescribing.

"We are hoping that pediatricians will pause before starting PPIs knowing that there is an increased risk of infections while their patients are on this drug," said Van Driest. "If there is a need to start the drug, they can consider genetic testing to find out their patient's CYP2C19 status."

Van Driest's team was made up of members from the Department of Pediatrics, Biomedical Informatics, Medicine and Pharmacology from Vanderbilt as well as one member of the Nemours Children's Health System in Florida.

 
Share:

Related Articles:


Recent Articles

Study Finds Certain Genetic Test Not Useful in Predicting Heart Disease Risk

A Polygenic Risk Score -- a genetic assessment that doctors have hoped could predict coronary heart disease (CHD) in patients -- has been found not to be a useful predictive biomarker for disease risk, according to a Vanderbilt study published in the Journal of the American Medical Association.

Read More

Tennessee Infants Exposed to Hep C at Birth Often Not Tested for Virus

Most Tennessee infants exposed to hepatitis C at birth are not later tested to see if they acquired the virus, according to a study by researchers at Monroe Carell Jr. Children's Hospital at Vanderbilt and the Vanderbilt Center for Child Health Policy.

Read More

THA, TMA, TNA Outline Legislative Priorities

With the Tennessee General Assembly back in full swing, the state's major healthcare associations outline 2020 priorities.

Read More

Cardiac Innovation in Nashville

From transplants to trials, Nashville hospitals are leading the way in cardiac care.

Read More

A Modern Love Story: Where Technology, Healthcare & Construction Go Hand-in-Hand

Technology has changed every aspect of our lives. In fact, I had a healthy laugh a few weeks ago when I showed my children an old rotary phone and, get this, they did not know what it was.

Read More

Reeves/Smith Bill to Prevent Next Generation of Nicotine Addiction Garners Broad Industry Support

In late January, a group of more than 25 organizations from across Tennessee announced their support for legislation that seeks to prevent the next generation of nicotine addicts in the state.

Read More

Physician Spotlight: A Heart for Healing

TriStar Summit cardiologist Kristen Kerr is passionate about education, improving outcomes in women's heart health.

Read More

Heart Monitor

Read More

Ifetroban for Treating DMD-Associated Cardiomyopathy

Following successful preclinical trials and FDA funding, Cumberland Pharmaceuticals is preparing to launch a new Phase II trial of ifetroban to treat cardiomyopathy in Duchenne Muscular Dystrophy patients.

Read More

Endocrine Society Celebrates Progress from Bench to Bedside

Endocrine Society Chief Professional & Clinical Affairs Officer Robert Lash, MD, discusses the field, annual meeting, road shows and more.

Read More

Email Print
 
 

 

 


Tags:
None
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: